RL
Rajesh Laljibhai Vaishnav
About Rajesh Laljibhai Vaishnav
Rajesh Laljibhai Vaishnav has 20 years in corporate governance. Holds Managing Director and Designated Partner roles. Currently with 2 companies, including Nano Therapeutics Private Limited and Transcath Therapeutics Llp. Formerly with 1 company, such as Miv Therapeutics (India) Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Nano Therapeutics Private Limited
U33114GJ2008PTC082936
|
Managing Director | 19 Feb 2016 | 2008 | Active |
Transcath Therapeutics Llp
AAF-8674
|
Designated Partner | 07 Mar 2016 | 2016 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Miv Therapeutics (India) Private Limited
U33112GJ2006PTC048811
|
Whole-Time Director | 01 Aug 2006 | 2006 | Amalgamated |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Rajesh Laljibhai Vaishnav
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rajesh Laljibhai Vaishnav
Rajesh Laljibhai Vaishnav has 20 years in corporate governance. Holds Managing Director and Designated Partner roles. Currently with 2 companies, including Nano Therapeutics Private Limited and Transcath Therapeutics Llp. Formerly with 1 company, such as Miv Therapeutics (India) Private Limited. Engaged in General Business. Contributes to corporate operations.
Rajesh Laljibhai Vaishnav is associated with 2 companies as Managing Director and Designated Partner.
Rajesh Laljibhai Vaishnav has expertise in General Business.
Rajesh Laljibhai Vaishnav has 20 years in corporate governance.